Advertisement

Molecular Medicine

, Volume 16, Issue 9–10, pp 433–437 | Cite as

Stem Cell Transplantation in Brain Tumors: A New Field for Molecular Imaging?

  • Nora Sandu
  • Bernhard Schaller
Mini-Review

Abstract

Neural stem cells have been proposed as a new and promising treatment modality in various pathologies of the central nervous system, including malignant brain tumors. However, the underlying mechanism by which neural stem cells target tumor areas remains elusive. Monitoring of these cells is currently done by use of various modes of molecular imaging, such as optical imaging, magnetic resonance imaging and positron emission tomography, which is a novel technology for visualizing metabolism and signal transduction to gene expression. In this new context, the microenvironment of (malignant) brain tumors and the blood-brain barrier gains increased interest. The authors of this review give a unique overview of the current molecular-imaging techniques used in different therapeutic experimental brain tumor models in relation to neural stem cells. Such methods for molecular imaging of gene-engineered neural stem/progenitor cells are currently used to trace the location and temporal level of expression of therapeutic and endogenous genes in malignant brain tumors, closing the gap between in vitro and in vivo integrative biology of disease in neural stem cell transplantation.

References

  1. 1.
    Yip S, et al. (2003) Neural stem cell biology may be well suited for improving brain-tumor therapies. Cancer. J. 9:189–204.CrossRefGoogle Scholar
  2. 2.
    Thu MS, et al. (2009) Iron labelling and preclinical MRI visualization of therapeutic human neural stem cell in a murine gliome model. PLoSOne. 4:e7218.CrossRefGoogle Scholar
  3. 3.
    Schaller B. (2003) Neuroprotection in brain tumors: good sense or nonsense from the pathophysiological viewpoint? Nervenarzt. 74:134–6.CrossRefGoogle Scholar
  4. 4.
    Schaller BJ, Buchfelder M. (2006) Neuroprotection in primary brain tumors: sense or nonsense? Expert Rev. Neurother. 6:723–30.CrossRefGoogle Scholar
  5. 5.
    Schaller BJ, Cornelius JF, Sandu N, Buchfelder M. (2008) Molecular imaging of brain tumors: Personal experience and review of the literature. Curr. Mol. Med. 8:711–26.CrossRefGoogle Scholar
  6. 6.
    Schaller B, Cornelius JF, Sandu N. (2008) Molecular medicine successes in neuroscience. Mol. Med. 14:361–4.CrossRefGoogle Scholar
  7. 7.
    Kosztowski T, Zaidi HA, Quinones-Hinojasa A. (2009) Application of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev. Anticancer Ther. 9:597–612.CrossRefGoogle Scholar
  8. 8.
    Schaller B. (2005) Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis. Acta Neurol. Scand. 111:75–83.CrossRefGoogle Scholar
  9. 9.
    Zhao P, et al. (2008) Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol. Cancer Res. 6:1819–29.Google Scholar
  10. 10.
    Matuski E, et al. (2009) Cell adhesion markers in ischaemic stroke patients: correlation with clinical outcome and comparison with primary autoimmune disease. Arch. Med. Sci. 5:182–9.Google Scholar
  11. 11.
    Schaller BJ. (2006) The role of endothelin in stroke: experimental data and underlying pathophysiology. Arch. Med. Sci. 2:146–58.Google Scholar
  12. 12.
    Schaller B. (2005) Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance. Neurosci. Let. 377:206–11.CrossRefGoogle Scholar
  13. 13.
    Oliver L, Olivier C, Marhuenda FB, Campone M, Vallette FM. (2009) Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr. Mol. Pharmacol. 2:263–84.CrossRefGoogle Scholar
  14. 14.
    Schaller B, Graf R. (2004) Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. J. Cereb. Blood Flow Metab. 24:351–71.CrossRefGoogle Scholar
  15. 15.
    Schaller BJ, Modo M, Buchfelder M. (2007) Molecular imaging of brain tumors: A bridge between clinical and molecular medicine? Mol. Imaging Biol. 9:60–71.CrossRefGoogle Scholar
  16. 16.
    Schaller B, Cornelius JF, Sandu N, Ottaviani G, Perez-Pinzon MA. (2009) Oxygen-conserving reflexes of the brain: the current molecular knowledge. J. Cell Mol. Med. 13:644–7.CrossRefGoogle Scholar
  17. 17.
    Aboody K, et al. (2000) Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc. Natl. Acad. Sci. U. S. A. 97:12846–51.CrossRefGoogle Scholar
  18. 18.
    Benedetti S, et al. (2000) Gene therapy of experimental brain tumors using neural progenitor cells. Nat. Med. 6:447–50.CrossRefGoogle Scholar
  19. 19.
    Schmidt NO, et al. (2005) Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia. 7:623–9.CrossRefGoogle Scholar
  20. 20.
    Staflin K, et al. (2004) Neural progenitor cell lines rat inhibit tumor growth in vivo. Cancer Res. 64:5347–54.CrossRefGoogle Scholar
  21. 21.
    Ethesham M, et al. (2002) The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. 62:5657–63.Google Scholar
  22. 22.
    Fomchenko EI, Holland EC. (2005) Stem cells and brain cancer. Exp. Cell Res. 306:323–9.CrossRefGoogle Scholar
  23. 23.
    Modo M, Roberts TJ, Sandhu JK, Williams SCR. (2004) In vivo monitoring of cellular transplants by magnetic resonance imaging and positron emission tomography. Expert Opin. Bio. Ther. 4:145–55.CrossRefGoogle Scholar
  24. 24.
    Zlokovic BV, Apuzzo ML. (1997) Cellular and molecular neurosurgery: Pathways from concept to reality, part 1: target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery. 40:789–803.CrossRefGoogle Scholar
  25. 25.
    Marchi N, et al. (2010) Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity. BMC Neurosci. 9:11–34.Google Scholar
  26. 26.
    Gera A, Steinberg GK, Guzman R. (2010) In vivo neural stem cell imaging: Current modalities and future directions. Regen. Med. 5:73–86.CrossRefGoogle Scholar
  27. 27.
    Rapoport SI, Hori M, Klatzo I. (1972) Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am. J. Physiol. 223:323–31.PubMedGoogle Scholar
  28. 28.
    Kurozumi K, et al. (2007) Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J. Natl. Cancer Inst. 99:1768–81.CrossRefGoogle Scholar
  29. 29.
    Bradbury MS, et al. (2007) Optical bioluminescence imaging of human ES cell progeny in the rodent CNS. J. Neurochem. 102:2029–39.CrossRefGoogle Scholar
  30. 30.
    Wilson K, Yu J, Lee A, Wu JC. (2008) In vitro and in vivo bioluminescence reporter gene imaging of human embryonic stem cells. J. Vis. Exp. (14): 740.Google Scholar
  31. 31.
    Narsinh KH, Cao F, Wu JC. (2009) Molecular imaging of human embryonic stem cells. Methods Mol. Biol. 515:13–32.CrossRefGoogle Scholar
  32. 32.
    Jacobs AH, et al. (2003) PET-based molecular imaging in neuroscience. Eur. J. Nucl. Med. Mol. Imaging. 30:1051–65.CrossRefGoogle Scholar
  33. 33.
    Thu MS, et al. (2009) Iron labeling and preclinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS. 4:e7218.CrossRefGoogle Scholar
  34. 34.
    Modo M, et al. (2002) Tracking transplanted stem cell migration using bifunctional, contrast agent-enhanced, magnetic resonance imaging. Neuroimage. 17:803–11.CrossRefGoogle Scholar
  35. 35.
    Modo M, et al. (2004) Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. Neuroimage. 21:311–7.CrossRefGoogle Scholar
  36. 36.
    Corot C, Robert P, Idee JM, Port M. (2006) Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 58:1471–504.CrossRefGoogle Scholar
  37. 37.
    Modo M, Hoehn M, Bulte J. (2005) Cellular MR imaging. Mol. Imaging. 4:1Y21.CrossRefGoogle Scholar
  38. 38.
    Schaller BJ. (2008) Strategies for molecular imaging dementia and neurodegenerative diseases. Neuropsychiatr. Dis. Treat. 4:585–612.CrossRefGoogle Scholar
  39. 39.
    Chin BB, et al. (2003) 111In oxine labeled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nucl. Med. Commun. 24:1149–54.CrossRefGoogle Scholar
  40. 40.
    Jacobs A, et al. (2001) Quantitative kinetics of (124I)FIAU in cat and man. J. Nucl. Med. 42:467–75.PubMedGoogle Scholar
  41. 41.
    Pauwels EK, et al. (1998) FDG accumulation and tumor biology. Nucl. Med. Biol. 25:317–22.CrossRefGoogle Scholar
  42. 42.
    Weber WA, Schwaiger M, Avril N. (2007) Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl. Med. Biol. 27:683–7.CrossRefGoogle Scholar
  43. 43.
    Schaller B. (2004) Usefulness of positron emission tomography in diagnosis and treatment follow-up of brain tumors. Neurobiol. Dis. 15:437–48.CrossRefGoogle Scholar
  44. 44.
    Shah K, Hsich G, Breakefield XO. (2004) Neural precursor cells and their role in neuro-oncology. Dev. Neurosci. 26:118–30.CrossRefGoogle Scholar
  45. 45.
    Koehne G, et al. (2003) Serial in vivo imaging of targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat. Biotechnol. 21:405–13.CrossRefGoogle Scholar
  46. 46.
    Filmont JE, et al. (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest. 124:608–13.CrossRefGoogle Scholar
  47. 47.
    Becherer A, et al. (2002) Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia. 16:260–7.CrossRefGoogle Scholar
  48. 48.
    Spaepen K, et al. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with highdose chemotherapy and stem cell transplantation. Blood. 102:53–9.CrossRefGoogle Scholar
  49. 49.
    Cremerius U, et al. (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkins lymphoma. Bone Marrow Transplant. 30:103–11.CrossRefGoogle Scholar
  50. 50.
    Su H, Forbes A, Gamghir SS, Braun J. (2004) Quantization of cell number by a positron emission tomography reporter gene strategy. Mol. Imaging Biol. 6:139–48.CrossRefGoogle Scholar
  51. 51.
    Brower V. (2005) Search and destroy: recent research exploits adult stem cells’ attraction to cancer. J. Natl. Cancer Inst. 97:414–6.CrossRefGoogle Scholar
  52. 52.
    De Witte O, et al. (2000) FDG-PET as a prognostic factor in high-grade astrocytoma. J. Neurooncol. 49:157–63.CrossRefGoogle Scholar
  53. 53.
    Padma MV, et al. (2003) Prediction of pathology and survival by FDG PET in gliomas. J. Neurooncol. 64:227–37.CrossRefGoogle Scholar
  54. 54.
    Shah K, et al. (2008) Biomodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J. Neurosci. 28:4406–13.CrossRefGoogle Scholar
  55. 55.
    Brekke C, et al. (2007) Cellular multiparametric MRI of neural stem cell therapy in a rat glioma model. Neuroimage. 37:769–82.CrossRefGoogle Scholar
  56. 56.
    Anderson SA, et al. (2005) Noninvasive MR imaging of magnetically labelled stem cells to directly identify neovasculature in a glioma model. Blood. 105:420–5.CrossRefGoogle Scholar
  57. 57.
    Hata N, et al. (2010) Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 66:144–56.CrossRefGoogle Scholar
  58. 58.
    Miletic H, et al. (2007) Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol. Ther. 15:1373–81.CrossRefGoogle Scholar
  59. 59.
    Shah K, Weissleder R. (2005) Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx 2:215–25.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2010

Authors and Affiliations

  1. 1.Department of NeurosurgeryUniversity of LausanneLausanneSwitzerland
  2. 2.Department of NeurosurgeryUniversity of ParisParisFrance
  3. 3.University of OradeaBucharestRomania

Personalised recommendations